The first-in-class glutaminase inhibitor CB-839 showed encouraging activity and tolerability when combined with everolimus and cabozantinib in heavily pretreated patients with metastatic renal cell carcinoma, according to results from a phase I study presented in a poster session at the 2018 Genitourinary Cancers Symposium in San Francisco, California.
The first-in-class glutaminase inhibitor CB-839 showed encouraging activity and tolerability when combined with everolimus (Afinitor) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC), according to results from a phase I study presented in a poster session at the 2018 Genitourinary Cancers Symposium in San Francisco, California.
CB-839, which is being developed by Calithera Biosciences, Inc, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase, a pathway that is upregulated in kidney cancer. CB-839’s onco-metabolism activity takes advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells such as cytotoxic T-cells. It is currently being evaluated in phase II clinical trials in multiple tumor types in combination with standard-of-care agents.
The open-label study was conducted in 2 parts. Part 1 was a dose-escalation study which enrolled patients with locally advanced, metastatic and/or refractory solid tumors who received CB-839 capsules orally 2 or 3 times daily.
Part 2 enrolled patients with triple-negative breast cancer (TNBC), nonsmall cell lung cancer (NSCLC), RCC, mesothelioma, fumarate hydratase-deficient tumors, succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumors (GIST), SDH-deficient non-GIST tumors, tumors harboring mutations in isocitrate dehydrogenase-1 (IDH1) orIDH2, and tumors harboring amplifications in c-MYC.
As an extension of parts 1 and 2, patients were treated with CB-839 in combination with chemotherapy. Patients with locally advanced or metastatic TNBC were treated with paclitaxel and CB-839, patients with advanced clear cell RCC or papillary RCC were treated with everolimus in combination with CB-839, patients with advanced NSCLC lacking theEGFRT790M mutation were treated with erlotinib (Tarceva) and CB-839, patients with NSCLC harboringKRASmutations were treated with docetaxel and CB-839, and patients with histologically confirmed diagnosis of locally advanced, inoperable, or metastatic RCC treated with cabozantinib in combination with CB-839.
Findings of 12 patients with mRCC treated with CB-839 and everolimus who were evaluable for response by the data cutoff were presented in a poster by Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, et al. Of the evaluable patients, 10 had clear cell RCC, and 2 had papillary disease. Some degree of tumor shrinkage and disease control was experienced by each patient, including 4 patients who had a partial response (PR) and 8 patients who had stable disease (SD). In the clear cell patient population, the disease control rate was 100% and the response rate was 40%.
Findings were also presented of 24 evaluable patients who received the combination of CB-839 and everolimus. The disease control rate was 92%, including 1 patient with a PR and 21 patients with SD. The median progression-free survival (PFS) was 5.8 months.
A total of 27 patients were enrolled in the CB-839/everolimus (n = 17) and expansion (n = 10) cohorts (7 at 400 mg/kg dosage, 13 at 600 mg/kg, 7 at 800 mg/kg) and 11 patients (9 with clear cell histology and 2 with papillary) were enrolled in the CB-839/cabozantinib escalation cohorts.
Eligibility criteria included mRCC with clear cell or papillary histology, an ECOG performance status of 0 or 1, and RECIST measurable disease. Patients with clear cell histology were required to have received prior treatment with at least 1 anti-VEGF therapy.
Patients were administered CB-839 in oral doses that ranged from 600 to 800 mg twice a day (6 at 600 mg/kg, 5 at 800 mg/kg) in combination with fixed standard oral doses of cabozantinib and everolimus.
Patients in the CB-839/everolimus group had a median of 2 prior lines of therapy, including 64% of clear cell patients who had received ≥2 prior anti-VEGF therapies. Patients in the CB-839/cabozantinib group had a median of 3 prior therapies (range, 0-6), including tyrosine kinase inhibitors, mTOR inhibitors, and checkpoint inhibitors. A maximum-tolerated dose was not reached; 800 mg/kg was selected as the recommended phase II dose for CB-839.
The most common treated-related adverse events of grade 3 or greater were fatigue (11%), anemia, hyperglycemia, and neutropenia (7% each) for CB-839/everolimus (n = 27), and diarrhea (14%) and platelet count decrease (14%), including 1 dose-limiting toxicity at 600 mg, for CB-839/cabozantinib (n = 7).
Based on this efficacy and safety data, Calithera Biosciences, Inc. has initiated the randomized phase II ENTRATA trial of CB-839 in combination with everolimus in later-stage patients. The trial is currently enrolling and is expected to enroll approximately 65 patients.
The company also plans to initiate the CANTATA trial, a phase II randomized, placebo-controlled trial in approximately 300 patients with clear-cell RCC who have previously received 1 or 2 prior lines of therapy. The trial is expected to begin in the second quarter of 2018.
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen